A Phase II Multi-Center Randomized, Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of R05285119 in Children with ASD
Project Description:
A Phase II Multi-Center Randomized, Double-Blind, 24-Week, 3-Arm, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of R05285119 in Children and Adolescents Age 5-17 with Autism Spectrum Disorder
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Professionals and Para-Professionals
Unserved or Under-served Populations:
None
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A